You’ve hit your GLP-1 goal weight. Here are the questions to ask your prescriber next.

The conversation you had when starting a GLP-1 was about side effects, titration, and what to expect in the first few months. The maintenance conversation is different. It’s about:

• Whether ongoing pharmacotherapy makes sense for you long-term
• What happens biologically if you stop
• How to protect the metabolic and body composition gains you’ve made
• What your prescriber’s threshold is for adjusting or stopping
• Who pays for ongoing treatment, and whether that changes

These are questions with real stakes. Going into them without preparation leaves you in a reactive position.

1. Should I maintain my current dose, reduce it, or consider stopping — and what’s the clinical rationale?

This is the central question. Your prescriber may recommend continuing the current dose to sustain results, or may consider a lower dose appropriate for maintenance rather than active loss. The answer should be individualized, not default.

2. What do we expect to happen to hunger and food-related thinking if the dose is reduced?

“Food noise” — the persistent mental preoccupation with food that GLP-1s suppress — often returns at lower doses or after stopping. Ask your prescriber what’s realistic to expect, and how you’ll both know if a dose reduction is causing a problem.

3. How are we protecting muscle mass and body composition?

Weight loss on a GLP-1 includes both fat and lean muscle. In maintenance, preventing further muscle loss through resistance training and adequate protein intake matters for long-term metabolic health. Ask whether your prescriber wants to monitor body composition, not just scale weight.

4. What cardiometabolic markers should we track?

If your blood pressure, fasting glucose, or lipids improved alongside your weight loss, those need to be monitored as your weight stabilizes and if your dose changes. Ask what the monitoring plan looks like.

5. What does my insurance cover long-term, and should we figure that out now?

Insurance coverage for GLP-1 medications varies by plan and can change at renewal. If your plan only covers the drug for active weight loss and not maintenance, you need to know before that becomes a crisis. Ask early.

6. Is an oral GLP-1 option worth considering for maintenance?

Oral semaglutide (Wegovy tablets, 25 mg) is FDA-approved for weight management. Phase 3b data from the ATTAIN-MAINTAIN trial suggest oral orforglipron may also be a maintenance option once it receives FDA approval. Ask your prescriber whether a transition to an oral formulation makes sense for your situation.

7. What is the plan if I regain more than [X] amount?

Establish a clear threshold with your prescriber for when to come back in and reassess. Don’t wait until you’ve regained a significant amount to reopen the conversation. Ask for a specific number and a specific plan.

8. What signs suggest I’m not managing well, and when should I come back sooner?

Some patients do well reducing or stopping. Others don’t. Ask what signals — in weight, in hunger, in energy, in mood — should prompt an earlier check-in.

A 2026 meta-regression in The Lancet eClinicalMedicine (PIIS2589-5370(26)00043-X) found that patients who stopped GLP-1 receptor agonists regained approximately 60% of their prior weight loss within one year. The regain curve was steepest in the first six months.

Data from the ATTAIN-MAINTAIN trial (Nature Medicine, 2026) found that patients who transitioned from injectable GLP-1s to oral orforglipron preserved 74.7–79.3% of their prior weight loss at 52 weeks — substantially better than the placebo group (38–49% preservation).

The takeaway: ongoing pharmacotherapy, even in a lower-intensity oral form, appears to substantially reduce the rate of weight regain compared to stopping entirely. But orforglipron is not yet FDA-approved. Your current options are the drugs your prescriber can actually prescribe today.

Food noise is one of the most underappreciated aspects of GLP-1 therapy. Many patients don’t fully realize how much it changed until it starts to return. At lower doses, some patients find appetite suppression diminishes noticeably. This is dose-dependent pharmacology, not a failure. Ask your prescriber what to expect.

Weight loss on a GLP-1 is not all fat. Studies consistently show that lean mass is also lost, especially without adequate protein intake and resistance training. In maintenance, the goal is to preserve the muscle you have. The scale doesn’t distinguish fat from muscle. If your prescriber isn’t thinking about body composition alongside weight, raise it explicitly.

If your current drug is covered for active weight loss but not indefinitely, you need a plan before coverage lapses. Options may include stepping down to a lower-dose branded option, switching to an oral formulation, or working with your prescriber on a supervised step-down. These conversations are easier to have in advance than in a crisis.

Whether any maintenance approach will work as well as continuous therapy is still being studied. Long-term data on dose-reduction strategies are limited. ATTAIN-MAINTAIN provides one data point — oral GLP-1 step-down — but covers only 52 weeks with a not-yet-approved drug. What your specific maintenance plan looks like depends on evidence that is still accumulating.

• Your current weight and goal weight, written down
• A list of any current side effects or concerns
• Your insurance plan documents and drug formulary
• This question list

It’s worth asking the front desk whether your prescriber has time for a maintenance planning conversation, not just a quick check-in. This topic deserves more than five minutes.

• Budini B et al. Trajectory of weight regain after cessation of GLP-1 receptor agonist treatment. The Lancet eClinicalMedicine, 2026. thelancet.com
• Aronne LJ et al. Orforglipron for maintenance of body weight reduction. Nature Medicine, 2026. nature.com
• ClinicalTrials.gov NCT06584916 (ATTAIN-MAINTAIN): clinicaltrials.gov

thelancet.com

nature.com

clinicaltrials.gov